Core Viewpoint - The company is focused on developing clinical data to demonstrate the value of its TULSA technology for prostate disease, positioning itself similarly to a biotech firm despite being a medical device company [1]. Group 1: Investment and Trials - The company has invested approximately $20 million to sponsor the most comprehensive Level 1 trial in the prostate cancer space [1]. - Results from the trial are beginning to be published and will continue to be reported over the next 10 years [1]. Group 2: Leadership and Expertise - Dr. Klotz, a highly regarded urologist, is involved in presenting the outcomes data from the trial [2].